GTx (GTXI) Receives News Sentiment Rating of 0.24

Headlines about GTx (NASDAQ:GTXI) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. GTx earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.5208475360316 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the headlines that may have impacted Accern’s scoring:

Shares of GTx (NASDAQ:GTXI) traded up 3.73% on Tuesday, hitting $8.34. The stock had a trading volume of 4,371 shares. GTx has a 52 week low of $0.65 and a 52 week high of $9.71. The company’s market capitalization is $133.92 million. The company has a 50-day moving average of $6.36 and a 200 day moving average of $5.15.

GTx (NASDAQ:GTXI) last issued its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.40) EPS for the quarter. On average, equities research analysts predict that GTx will post ($1.16) EPS for the current year.

Separately, ValuEngine upgraded GTx from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 13th.

WARNING: This piece of content was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at

GTx Company Profile

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Insider Buying and Selling by Quarter for GTx (NASDAQ:GTXI)

Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply